Timothy Keutzer

CIK: 0001798155

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (80.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SPRO

Spero Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

SPRO
Spero Therapeutics, Inc.
Feb 6, 2026
Sale(S)
Direct
18.7K shares at avg. $2.36$44K
SPRO
Spero Therapeutics, Inc.
Feb 4, 2026
Sale(S)
Direct
3.5K shares at avg. $2.24$8K
SPRO
Spero Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
24.2K shares at avg. $2.14$52K
SPRO
Spero Therapeutics, Inc.
Feb 2, 2026
Award(A)
Direct
68K shares-
SPRO
Spero Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
18.9K shares at avg. $2.20$42K
SPRO
Spero Therapeutics, Inc.
Aug 28, 2025
Sale(S)
Direct
1.7K shares at avg. $1.97$3K
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
24.9K shares at avg. $0.78$19K
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
27.6K shares at avg. $0.78$22K
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
4K shares at avg. $0.78$3K
SPRO
Spero Therapeutics, Inc.
Feb 3, 2025
Award(A)
Direct
266.1K shares-

		Type	Shares	Price		Ownership
Feb 6, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	18,652	$2.36	$44,019	Direct
Feb 4, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	3,471	$2.24	$7,775	Direct
Feb 3, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	24,224	$2.14	$51,839	Direct
Feb 2, 2026	SPRO Spero Therapeutics, Inc.	Award(A)	68,000	-	$0	Direct
Feb 2, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	18,891	$2.20	$41,560	Direct
Aug 28, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	1,695	$1.97	$3,339	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	24,920	$0.78	$19,438	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	27,643	$0.78	$21,562	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	3,974	$0.78	$3,100	Direct
Feb 3, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	266,139	-	-	Direct

1-10 of 10 transactions

About Keutzer Timothy

Keutzer Timothy (SEC CIK 0001798155) files insider reports with the SEC as Chief Operating Officer of Spero Therapeutics, Inc. (SPRO).

Signal8 holds 4 ownership filings by Keutzer Timothy, all Form 4s, filed between Feb 5, 2025 and Feb 9, 2026. Those filings report 10 transactions, from Feb 3, 2025 to Feb 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Keutzer Timothy's filings is in CAMBRIDGE, MA.

Recent filings by Keutzer Timothy

Feb 6, 2026: Open-market sale of SPRO shares (Form 4, code S).
Feb 4, 2026: Open-market sale of SPRO shares (Form 4, code S).
Feb 3, 2026: Open-market sale of SPRO shares (Form 4, code S).
Feb 2, 2026: Grant or award of SPRO shares (Form 4, code A).
Feb 2, 2026: Open-market sale of SPRO shares (Form 4, code S).

Other insiders filing for Spero Therapeutics, Inc. (SPRO)

Zack Debra, Chief Medical Officer
Deshpande Milind, Director
Tregoning Kathleen, Director
Smith Cynthia, Director
VINK PATRICK V.J.J., Director
THOMAS FRANK E, Director

How to read Form 4 transaction codes